APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ophthalmic AAV Gene Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Ophthalmic AAV Gene Therapy Market Outlook and Growth Opportunities 2026

26 December 2025191 pages

Choose your research edition.

Industry ResearchOphthalmic AAV Gene Therapy Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Ophthalmic AAV Gene Therapy Industry Growth and Trends Forecast to 203264 pages · $3,450 USDMarket StructureGlobal Ophthalmic AAV Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ophthalmic AAV Gene Therapy Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Ophthalmic AAV Gene Therapy Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Ophthalmic AAV Gene Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Ophthalmic AAV Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ophthalmic AAV Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ophthalmic AAV Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Ophthalmic AAV Gene Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Ophthalmic AAV Gene Therapy market include GenSight Biologics (Pipeline) and Spark/Roche (Luxturna) among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Ophthalmic AAV Gene Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ophthalmic AAV Gene Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ophthalmic AAV Gene Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Ophthalmic AAV Gene Therapy market.

Ophthalmic AAV Gene Therapy Segment by Company

GenSight Biologics (Pipeline)

Spark/Roche (Luxturna)

Ophthalmic AAV Gene Therapy Segment by Type

Subretinal Injection

Intravitreous Injection

Ophthalmic AAV Gene Therapy Segment by Application

Retinopathy

Optic Atrophy

Ophthalmic AAV Gene Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Ophthalmic AAV Gene Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Ophthalmic AAV Gene Therapy key companies, revenue, market share, and recent developments.

3. To split the Ophthalmic AAV Gene Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Ophthalmic AAV Gene Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ophthalmic AAV Gene Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Ophthalmic AAV Gene Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ophthalmic AAV Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ophthalmic AAV Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ophthalmic AAV Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ophthalmic AAV Gene Therapy industry.

Chapter 3: Detailed analysis of Ophthalmic AAV Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Ophthalmic AAV Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Ophthalmic AAV Gene Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ophthalmic AAV Gene Therapy Industry Trends Table 2. Ophthalmic AAV Gene Therapy Industry Drivers Table 3. Ophthalmic AAV Gene Therapy Industry Opportunities and Challenges Table 4. Ophthalmic AAV Gene Therapy Industry Restraints Table 5. Global Ophthalmic AAV Gene Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ophthalmic AAV Gene Therapy Revenue Share by Company (2021-2026) Table 7. Global Ophthalmic AAV Gene Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Ophthalmic AAV Gene Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Ophthalmic AAV Gene Therapy Company, Product Type & Application Table 10. Global Ophthalmic AAV Gene Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Ophthalmic AAV Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Subretinal Injection Table 15. Significant Companies of Intravitreous Injection Table 16. Global Ophthalmic AAV Gene Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Ophthalmic AAV Gene Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Ophthalmic AAV Gene Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Ophthalmic AAV Gene Therapy Sales Value Share by Type (2021-2026) Table 20. Global Ophthalmic AAV Gene Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Retinopathy Table 22. Significant Companies of Optic Atrophy Table 23. Global Ophthalmic AAV Gene Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Ophthalmic AAV Gene Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Ophthalmic AAV Gene Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Ophthalmic AAV Gene Therapy Sales Value Share by Application (2021-2026) Table 27. Global Ophthalmic AAV Gene Therapy Sales Value Share by Application (2027-2032) Table 28. Global Ophthalmic AAV Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Ophthalmic AAV Gene Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Ophthalmic AAV Gene Therapy Sales Value Share by Region (2021-2026) Table 31. Global Ophthalmic AAV Gene Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Ophthalmic AAV Gene Therapy Sales Value Share by Region (2027-2032) Table 33. Global Ophthalmic AAV Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Ophthalmic AAV Gene Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Ophthalmic AAV Gene Therapy Sales Value Market Share by Country (2021-2026) Table 36. Global Ophthalmic AAV Gene Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Ophthalmic AAV Gene Therapy Sales Value Market Share by Country (2027-2032) Table 38. GenSight Biologics (Pipeline) Company Information Table 39. GenSight Biologics (Pipeline) Business Overview Table 40. GenSight Biologics (Pipeline) Ophthalmic AAV Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. GenSight Biologics (Pipeline) Ophthalmic AAV Gene Therapy Product Portfolio Table 42. GenSight Biologics (Pipeline) Recent Development Table 43. Spark/Roche (Luxturna) Company Information Table 44. Spark/Roche (Luxturna) Business Overview Table 45. Spark/Roche (Luxturna) Ophthalmic AAV Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Spark/Roche (Luxturna) Ophthalmic AAV Gene Therapy Product Portfolio Table 47. Spark/Roche (Luxturna) Recent Development Table 48. Research Programs/Design for This Report Table 49. Authors List of This Report Table 50. Secondary Sources Table 51. Primary Sources List of Figures Figure 1. Ophthalmic AAV Gene Therapy Product Image Figure 2. Global Ophthalmic AAV Gene Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ophthalmic AAV Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Ophthalmic AAV Gene Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Subretinal Injection Image Figure 8. Intravitreous Injection Image Figure 9. Global Ophthalmic AAV Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Ophthalmic AAV Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Ophthalmic AAV Gene Therapy Sales Value Share by Type (2021-2032) Figure 12. Retinopathy Image Figure 13. Optic Atrophy Image Figure 14. Global Ophthalmic AAV Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Ophthalmic AAV Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Ophthalmic AAV Gene Therapy Sales Value Share by Application (2021-2032) Figure 17. Global Ophthalmic AAV Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Ophthalmic AAV Gene Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Ophthalmic AAV Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 20. North America Ophthalmic AAV Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Ophthalmic AAV Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Ophthalmic AAV Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Ophthalmic AAV Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Ophthalmic AAV Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Ophthalmic AAV Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. South America Ophthalmic AAV Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Ophthalmic AAV Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Ophthalmic AAV Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Subretinal Injection
  • Intravitreous Injection
Applications
  • Retinopathy
  • Optic Atrophy
Companies covered
  • GenSight Biologics (Pipeline)
  • Spark/Roche (Luxturna)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Ophthalmic AAV Gene Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Ophthalmic AAV Gene Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Ophthalmic AAV Gene Therapy Market Dynamics
  1. 2.1 Ophthalmic AAV Gene Therapy Industry Trends
  2. 2.2 Ophthalmic AAV Gene Therapy Industry Drivers
  3. 2.3 Ophthalmic AAV Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Ophthalmic AAV Gene Therapy Industry Restraints
3 Ophthalmic AAV Gene Therapy Market by Company
  1. 3.1 Global Ophthalmic AAV Gene Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Ophthalmic AAV Gene Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Ophthalmic AAV Gene Therapy Company Ranking (2024-2026)
  4. 3.4 Global Ophthalmic AAV Gene Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Ophthalmic AAV Gene Therapy Company Product Type and Application
  6. 3.6 Global Ophthalmic AAV Gene Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Ophthalmic AAV Gene Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Ophthalmic AAV Gene Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Ophthalmic AAV Gene Therapy Market by Type
  1. 4.1 Ophthalmic AAV Gene Therapy Type Introduction
  2. 4.1.1 Subretinal Injection
  3. 4.1.2 Intravitreous Injection
  4. 4.2 Global Ophthalmic AAV Gene Therapy Sales Value by Type
  5. 4.2.1 Global Ophthalmic AAV Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Ophthalmic AAV Gene Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Ophthalmic AAV Gene Therapy Sales Value Share by Type (2021-2032)
5 Ophthalmic AAV Gene Therapy Market by Application
  1. 5.1 Ophthalmic AAV Gene Therapy Application Introduction
  2. 5.1.1 Retinopathy
  3. 5.1.2 Optic Atrophy
  4. 5.2 Global Ophthalmic AAV Gene Therapy Sales Value by Application
  5. 5.2.1 Global Ophthalmic AAV Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Ophthalmic AAV Gene Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global Ophthalmic AAV Gene Therapy Sales Value Share by Application (2021-2032)
6 Ophthalmic AAV Gene Therapy Regional Value Analysis
  1. 6.1 Global Ophthalmic AAV Gene Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ophthalmic AAV Gene Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Ophthalmic AAV Gene Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Ophthalmic AAV Gene Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Ophthalmic AAV Gene Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Ophthalmic AAV Gene Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Ophthalmic AAV Gene Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Ophthalmic AAV Gene Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Ophthalmic AAV Gene Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Ophthalmic AAV Gene Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Ophthalmic AAV Gene Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Ophthalmic AAV Gene Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Ophthalmic AAV Gene Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Ophthalmic AAV Gene Therapy Sales Value Share by Country, 2025 VS 2032
7 Ophthalmic AAV Gene Therapy Country-level Value Analysis
  1. 7.1 Global Ophthalmic AAV Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ophthalmic AAV Gene Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Ophthalmic AAV Gene Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Ophthalmic AAV Gene Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Ophthalmic AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Ophthalmic AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Ophthalmic AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GenSight Biologics (Pipeline)
  2. 8.1.1 GenSight Biologics (Pipeline) Company Information
  3. 8.1.2 GenSight Biologics (Pipeline) Business Overview
  4. 8.1.3 GenSight Biologics (Pipeline) Ophthalmic AAV Gene Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GenSight Biologics (Pipeline) Ophthalmic AAV Gene Therapy Product Portfolio
  6. 8.1.5 GenSight Biologics (Pipeline) Recent Developments
  7. 8.2 Spark/Roche (Luxturna)
  8. 8.2.1 Spark/Roche (Luxturna) Company Information
  9. 8.2.2 Spark/Roche (Luxturna) Business Overview
  10. 8.2.3 Spark/Roche (Luxturna) Ophthalmic AAV Gene Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Spark/Roche (Luxturna) Ophthalmic AAV Gene Therapy Product Portfolio
  12. 8.2.5 Spark/Roche (Luxturna) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst